Patients Responding to global greying: Does Nordic AgeTech hold the b... It’s a fact of life that we’re all living longer, which is reshaping the way healthcare is delivered.
R&D Ageing Europe - It’s time we prioritised neurological condit... Europeans are living longer than ever before – tangible proof of the phenomenal advancements in science and healthcare.1,2 However, it comes with a paradoxical rise in nervous sy
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
